LENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives $29.80 Consensus Target Price from Analysts

Posted by on Aug 6th, 2026

Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ – Get Free Report) have received a consensus rating of “Hold” from the eight analysts that are covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $29.80.

A number of equities research analysts recently commented on the company. HC Wainwright reiterated a “buy” rating on shares of LENZ Therapeutics in a research report on Tuesday, July 7th. Citigroup reduced their price target on shares of LENZ Therapeutics from $26.00 to $20.00 and set a “buy” rating for the company in a research report on Wednesday, May 13th. Piper Sandler cut shares of LENZ Therapeutics from an “overweight” rating to a “neutral” rating and decreased their price objective for the company from $39.00 to $12.00 in a research note on Tuesday, May 12th. Zacks Research downgraded shares of LENZ Therapeutics from a “hold” rating to a “strong sell” rating in a report on Wednesday, July 15th. Finally, Weiss Ratings upgraded shares of LENZ Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, June 17th.

Get Our Latest Report on LENZ Therapeutics

Institutional Investors Weigh In On LENZ Therapeutics

Several hedge funds have recently added to or reduced their stakes in LENZ. Tower Research Capital LLC TRC lifted its holdings in LENZ Therapeutics by 51.4% in the second quarter. Tower Research Capital LLC TRC now owns 1,405 shares of the company’s stock valued at $41,000 after acquiring an additional 477 shares during the period. Quarry LP purchased a new stake in LENZ Therapeutics in the 3rd quarter worth approximately $27,000. JPMorgan Chase & Co. grew its stake in shares of LENZ Therapeutics by 8.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 11,222 shares of the company’s stock worth $523,000 after purchasing an additional 861 shares during the period. BNP Paribas Financial Markets grew its stake in shares of LENZ Therapeutics by 93.7% during the 2nd quarter. BNP Paribas Financial Markets now owns 1,951 shares of the company’s stock worth $57,000 after purchasing an additional 944 shares during the period. Finally, Osaic Holdings Inc. increased its holdings in shares of LENZ Therapeutics by 2,146.2% during the 2nd quarter. Osaic Holdings Inc. now owns 1,168 shares of the company’s stock valued at $34,000 after purchasing an additional 1,116 shares in the last quarter. 54.32% of the stock is owned by hedge funds and other institutional investors.

LENZ Therapeutics Stock Performance

LENZ Therapeutics stock opened at $5.27 on Thursday. The business’s 50-day simple moving average is $5.96 and its two-hundred day simple moving average is $9.65. The company has a market cap of $165.21 million, a PE ratio of -1.46 and a beta of 0.65. LENZ Therapeutics has a fifty-two week low of $4.68 and a fifty-two week high of $50.40.

LENZ Therapeutics (NASDAQ:LENZ – Get Free Report) last announced its quarterly earnings data on Monday, May 11th. The company reported ($1.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.10) by ($0.22). LENZ Therapeutics had a negative net margin of 519.30% and a negative return on equity of 46.82%. The firm had revenue of $1.90 million during the quarter, compared to analyst estimates of $1.76 million. As a group, analysts predict that LENZ Therapeutics will post -4.63 EPS for the current fiscal year.

About LENZ Therapeutics

(Get Free Report)

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

Featured Stories

Analyst Recommendations for LENZ Therapeutics (NASDAQ:LENZ)

Receive News & Ratings for LENZ Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LENZ Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.